GE vs PFE: Which Is the Better Buy?
Side-by-side comparison of GE Aerospace and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-16.
GE Aerospace · Industrials
$360.35
-25.9% upside to fair value
Grade D
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GE |
PFE |
| Current Price |
$360.35 |
$25.22 |
| Fair Value Estimate |
$267.03 |
$25.92 |
| Upside to Fair Value |
-25.9%
|
+2.8%
|
| Market Cap |
$376.5B |
$143.7B |
| Forward P/E |
42.3x
|
19.2x
|
| EV / EBITDA |
33.4x
|
12.3x
|
| Price / Sales |
7.8x
|
2.3x
|
| Price / FCF |
50.5x
|
15.2x
|
| Revenue Growth YoY |
+21.1%
|
+5.4%
|
| Gross Margin |
36.1%
|
69.3%
|
| Operating Margin |
21.0%
|
23.4%
|
| Return on Equity |
46.2%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.98%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
GE Aerospace operates in the Industrials sector within the Aerospace & Defense industry, delivering high-quality aerospace products and services. The business demonstrates strong fundamentals with a high return on equity of 46.2%, robust revenue growth of 21.1% in the most recent quarter, and solid earnings growth of 16.9% in the same period. Margins are healthy, with a gross margin of 36.1%, ope…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
GE |
PFE |
| Zone Low |
$200.27 |
$19.44 |
| Zone High |
$226.98 |
$22.03 |
| In Buy Zone? |
No
|
No
|